Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by SouthernTierTomon Mar 22, 2022 9:34am
214 Views
Post# 34533961

RE:Contact Birch Hill or our legal rep at Stikeman Elliot

RE:Contact Birch Hill or our legal rep at Stikeman ElliotWe are going to need disclosure on the 'Alter-cyte' arrangement ( circa 2012 )  The company was questioned about this "arrangement" and shareholders were not provided any answers.  We were told "it might be important down the road, and for now it was not important"

We also want to know WHO received the 1.7M CAD "one-time charge" that "tanked the quarter" and kick-started the near 70M share dilution party on the back of too many advances to mention ( though there is a list )

It appears as though things aren't nearly "johnny come-lately" as we are led to believe.  I've known this for over a decade.

Whether it is the company, the board or the our Stikeman rep, we need clarification on Alter-cyte;

DR PAUL WALKER COWORKERS AT ALTERCYTE INC. (5)
Dr John Kellum
Shareholder at Altercyte Inc. · Pittsburgh
Dr Kai Singbartl
Shareholder at Altercyte Inc. · Pittsburgh
David Valenti
Administrative Assistant at Altercyte Inc. · Pittsburgh
Dr William Federspiel
Shareholder at Altercyte Inc. · Pittsburgh
Anthony Businskas
Chief Financial Officer at Altercyte Inc. · Pittsburgh
<< Previous
Bullboard Posts
Next >>